PL2281576T3 - Polimerowa micela typu aktywnie ukierunkowującego, niosąca zamknięty w niej lek i kompozycja medyczna - Google Patents

Polimerowa micela typu aktywnie ukierunkowującego, niosąca zamknięty w niej lek i kompozycja medyczna

Info

Publication number
PL2281576T3
PL2281576T3 PL09803068T PL09803068T PL2281576T3 PL 2281576 T3 PL2281576 T3 PL 2281576T3 PL 09803068 T PL09803068 T PL 09803068T PL 09803068 T PL09803068 T PL 09803068T PL 2281576 T3 PL2281576 T3 PL 2281576T3
Authority
PL
Poland
Prior art keywords
medicinal composition
polymeric micelle
active targeting
type polymeric
carrying drug
Prior art date
Application number
PL09803068T
Other languages
English (en)
Inventor
Yasuki Kato
Mitsunori Harada
Hiroyuki Saito
Tatsuyuki Hayashi
Original Assignee
Nanocarrier Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanocarrier Co Ltd filed Critical Nanocarrier Co Ltd
Publication of PL2281576T3 publication Critical patent/PL2281576T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/644—Transferrin, e.g. a lactoferrin or ovotransferrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL09803068T 2008-07-29 2009-07-29 Polimerowa micela typu aktywnie ukierunkowującego, niosąca zamknięty w niej lek i kompozycja medyczna PL2281576T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2008194825 2008-07-29
PCT/JP2009/063838 WO2010013836A1 (ja) 2008-07-29 2009-07-29 薬物内包アクティブターゲット型高分子ミセル、医薬組成物
EP09803068.7A EP2281576B1 (en) 2008-07-29 2009-07-29 Active targeting type polymeric micelle carrying drug enclosed therein and medicinal composition

Publications (1)

Publication Number Publication Date
PL2281576T3 true PL2281576T3 (pl) 2013-12-31

Family

ID=41610525

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09803068T PL2281576T3 (pl) 2008-07-29 2009-07-29 Polimerowa micela typu aktywnie ukierunkowującego, niosąca zamknięty w niej lek i kompozycja medyczna

Country Status (13)

Country Link
US (1) US8741339B2 (pl)
EP (1) EP2281576B1 (pl)
JP (1) JP4538666B2 (pl)
KR (2) KR20100055498A (pl)
CN (1) CN101808668B (pl)
AU (1) AU2009277456B2 (pl)
CA (1) CA2695611C (pl)
DK (1) DK2281576T3 (pl)
ES (1) ES2432152T3 (pl)
HK (1) HK1148216A1 (pl)
PL (1) PL2281576T3 (pl)
PT (1) PT2281576E (pl)
WO (1) WO2010013836A1 (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8524784B2 (en) 2009-04-30 2013-09-03 Intezyne Technologies, Incorporated Polymer micelles containing anthracylines for the treatment of cancer
EP2424359A4 (en) 2009-04-30 2014-01-15 Intezyne Technologies Inc POLYMIC MICELLES WITH ANTHRACYCLINES FOR THE TREATMENT OF CANCER
TWI533885B (zh) * 2011-03-31 2016-05-21 Nanocarrier Co Ltd And a pharmaceutical composition comprising a block copolymer containing a boronic acid compound
US9701740B2 (en) 2011-04-01 2017-07-11 Yale University Cell-penetrating anti-DNA antibodies and uses thereof inhibit DNA repair
MX2014005540A (es) 2011-11-17 2014-09-22 Univ Tokyo Copolimero en bloque que tiene un grupo acido fenilboronico introducido dentro de el y uso del mismo.
JP6195171B2 (ja) 2012-04-27 2017-09-13 国立大学法人 東京大学 核酸デリバリー用ユニット構造型医薬組成物
JP5692887B1 (ja) * 2013-05-17 2015-04-01 ナノキャリア株式会社 ポリマーミセル医薬組成物
WO2015170757A1 (ja) 2014-05-08 2015-11-12 国立大学法人 東京大学 医薬組成物
WO2016161102A1 (en) * 2015-04-02 2016-10-06 The Research Foundation For The State University Of New York A supramolecular chitosan complex drug delivery platform
US20190330317A1 (en) 2016-06-15 2019-10-31 Yale University Anti-guanosine antibody as a molecular delivery vehicle
WO2017218825A1 (en) 2016-06-15 2017-12-21 Yale University Antibody-mediated autocatalytic, targeted delivery of nanocarriers to tumors
WO2018025699A1 (ja) * 2016-08-02 2018-02-08 日本化薬株式会社 アクティブターゲティング型高分子誘導体、その高分子誘導体を含む組成物、及びそれらの用途
JP6644326B2 (ja) 2017-08-31 2020-02-12 国立大学法人 東京大学 核酸搭載ユニット型ポリイオンコンプレックス
CN115003285B (zh) * 2020-01-15 2024-05-14 超新星生物有限公司 用于减少局部脂肪的气体发泡型胶束
EP4408457A1 (en) 2021-09-30 2024-08-07 Yale University Compositions and methods for the treatment of autosomal dominant polycystic kidney disease and other diseases having upregulated mtor activity
JP2023138437A (ja) * 2022-03-17 2023-10-02 日油株式会社 ポリエチレングリコール誘導体の製造方法
WO2024050524A1 (en) 2022-09-01 2024-03-07 University Of Georgia Research Foundation, Inc. Compositions and methods for directing apolipoprotein l1 to induce mammalian cell death

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002087497A2 (en) * 2001-04-26 2002-11-07 Board Of Regents, The University Of Texas System Therapeutic agent/ligand conjugate compositions, their methods of synthesis and use
CA2444483A1 (en) * 2001-04-26 2002-11-07 Board Of Regents, The University Of Texas System Diagnostic imaging compositions, their methods of synthesis and use
US7371781B2 (en) * 2003-09-22 2008-05-13 University Of Utah Research Foundation Tumor environment-induced ligand-expressing nanocarrier system
WO2005120585A1 (en) * 2004-06-04 2005-12-22 Case Western Reserve University Dual function polymer micelles
NZ562064A (en) * 2005-04-01 2011-03-31 Intezyne Technologies Inc Polymeric micelles for drug delivery
EP1878766B1 (en) * 2005-05-02 2020-01-01 The University of Tokyo Electrostatic bonding type polymer vesicle
WO2007048121A2 (en) * 2005-10-20 2007-04-26 Centocor, Inc. Methods of preparing targeted immunoliposomes
JP5028564B2 (ja) * 2005-10-31 2012-09-19 宮崎県 肝疾患治療用又は予防用の血中滞留型多相エマルション製剤及びその製造方法
JP5046957B2 (ja) 2005-12-05 2012-10-10 ナノキャリア株式会社 フッ素系有機溶媒を用いた薬物封入ポリマーミセルを含有する医薬組成物の製造方法
EP2011516A4 (en) * 2006-04-24 2010-06-23 Nanocarrier Co Ltd PROCESS FOR THE PRODUCTION OF A POLYMERIC MICELLE THAT CONTAINS A CHEMICAL PRODUCT OF LOW MOLECULAR WEIGHT ENCAPSULATED IN IT
KR101444274B1 (ko) * 2006-10-19 2014-09-26 나노캬리아 가부시키가이샤 약제복합체용 블록 공중합체 및 의약조성물
US20080248097A1 (en) * 2007-02-26 2008-10-09 Kwon Glen S Polymeric micelles for combination drug delivery

Also Published As

Publication number Publication date
KR20110075054A (ko) 2011-07-05
US20100221320A1 (en) 2010-09-02
HK1148216A1 (en) 2011-09-02
CN101808668B (zh) 2012-06-27
CA2695611C (en) 2011-02-01
AU2009277456A1 (en) 2010-02-04
EP2281576B1 (en) 2013-07-24
EP2281576A4 (en) 2011-07-20
US8741339B2 (en) 2014-06-03
AU2009277456B2 (en) 2011-05-26
WO2010013836A1 (ja) 2010-02-04
PT2281576E (pt) 2013-10-01
ES2432152T3 (es) 2013-12-02
KR101468268B1 (ko) 2014-12-02
KR20100055498A (ko) 2010-05-26
CA2695611A1 (en) 2010-01-29
EP2281576A1 (en) 2011-02-09
DK2281576T3 (da) 2013-10-28
JP4538666B2 (ja) 2010-09-08
CN101808668A (zh) 2010-08-18
JPWO2010013836A1 (ja) 2012-01-12

Similar Documents

Publication Publication Date Title
PL2281576T3 (pl) Polimerowa micela typu aktywnie ukierunkowującego, niosąca zamknięty w niej lek i kompozycja medyczna
IL275854A (en) Pharmaceutical composition and its administration
IL234166B (en) Isoindoline compounds, a pharmaceutical composition containing it and its use in the preparation of a medicine
IL206553A (en) Immunoassays are targeted to cells expressing CD138, medicinal preparations and their containing kits and uses
EP2544701A4 (en) POLYMER CONJUGATES FOR DRUG DELIVERY AND METHOD FOR THE PRODUCTION AND USE THEREOF
IL206952A (en) History of Aminodia Hydrothiazine, medicinal preparations containing them, and their use in the preparation of medicines
IL207569A0 (en) Compositions and methods for drug delivery
ZA201206062B (en) Aminotetraline derivatives,pharmaceutical compositions containing them,and their use in therapy
IL212573A (en) Aryl Methyl Benzokinazulinone Compounds
IL213376A0 (en) Zaleplon gastroretentive drug delivery system and uses thereof
EP2203158A4 (en) PHARMACEUTICAL FORMULATIONS WITH TELMISARTAN AND HYDROCHLORTHIAZIDE
EP2170054A4 (en) TARGETING CONJUGATES WITH ACTIVE SUBSTANCES ENCAPLED IN CYCLODEXTRIN POLYMERS
IL222578A0 (en) Method for preparing pharmaceutical compositions intended for oral administration comprising one or more active ingredients and the compositions comprising same
HK1142536A1 (en) Gel useful for the delivery of cosmetic active ingredients
IL195764A0 (en) Compositions and methods for drug delivery
EP2153831A4 (en) ANTIERMÜDUNGSMITTEL AND ORAL COMPOSITION, BOTH WITH ANDROGRAPHOLIDE AS ACTIVE INGREDIENTS
EP2316449A4 (en) STABLE PHARMACEUTICAL COMPOSITION WITH TRANEXAMIC ACID AND ASCORBIC ACID
PT2056825E (pt) Utilização de formulações de opioide em dispositivos de fornecimento de fármaco sem agulha
EP2150235A4 (en) Capsule formulation coated with nanoparticles for the purpose of dermal drug administration
HK1142884A1 (zh) 對神經性疼痛有活性的藥物
ZA201104882B (en) Pharmaceutical compositions with superior product performance and patient compliance
EP2111222A4 (en) Dispensing Devices with Encapsulated and / or Partially Linked Pharmaceutical Ingredients
PL2240179T3 (pl) Imidazopirydazyny jako inhibitory PAR1, ich wytwarzanie i zastosowanie jako leku
IL207205A0 (en) Triazolopyridazines as par1 inhibitors, their preparation and use as medicaments
HK1155062A1 (en) Pharmaceutical composition and combined agent